Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis.
Hyaluronan, exhibiting a high resistance against water flow, acts in the tissue as a barrier against rapid changes in water content. To test whether hyaluronan has any effect on the peritoneal fluid and solute transport, and, in particular, on the peritoneal fluid absorption, a 4-h dwell study with an intraperitoneal volume marker (radiolabeled human serum albumin [RISA]) was conducted in 21 male Sprague Dawley rats (three groups, seven rats in each group). Each rat was injected intraperitoneally with 25 ml of 1.36% glucose solution alone (control group), with 0.005% hyaluronan (HA1 group), or with 0.01% hyaluronan (HA2 group). Dialysate and blood samples were taken frequently for analyses of fluid and solute (urea, glucose, and protein) transport. The intraperitoneal volume was calculated from the dilution of RISA with a correction for RISA disappearance from the peritoneal cavity. This study shows that adding hyaluronan to peritoneal dialysis solution significantly (P < 0.01) increased the net peritoneal fluid removal, mainly due to a significant decrease in the peritoneal fluid absorption rate (P < 0.01). The diffusive mass transfer coefficients for glucose, urea, and protein did not differ between the three groups. The peritoneal clearance of urea increased significantly in the two hyaluronan groups compared with the control group, due to the increased net fluid removal in the hyaluronan groups. These results suggest that intraperitoneal administration of hyaluronan during a single peritoneal dialysis exchange may significantly increase the peritoneal fluid and solute removal by decreasing peritoneal fluid absorption.
Wang
T
T
Department of Clinical Science, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
Chen
C
C
Heimbürger
O
O
Waniewski
J
J
Bergström
J
J
Lindholm
B
B
D000042:Absorption / Q000187:drug effects; D000818:Animals; D001202:Ascitic Fluid / Q000378:metabolism*; D001692:Biological Transport / Q000187:drug effects; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000494:pharmacology*; D004058:Diffusion; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008954:Models, Biological; D010530:Peritoneal Dialysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012709:Serum Albumin / Q000493:pharmacokinetics; D014508:Urea / Q000378:metabolism
D015314:Dialysis Solutions; D012709:Serum Albumin; D014508:Urea; D006820:Hyaluronic Acid; D005947:Glucose